Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formation.

Ngamskulrungroj P, Chang Y, Hansen B, Bugge C, Fischer E, Kwon-Chung KJ.

FEMS Yeast Res. 2012 Nov;12(7):748-54. doi: 10.1111/j.1567-1364.2012.00824.x. Epub 2012 Jul 18.

2.

Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans.

Ngamskulrungroj P, Chang Y, Hansen B, Bugge C, Fischer E, Kwon-Chung KJ.

PLoS One. 2012;7(3):e33022. doi: 10.1371/journal.pone.0033022. Epub 2012 Mar 7.

3.

Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes.

Sionov E, Lee H, Chang YC, Kwon-Chung KJ.

PLoS Pathog. 2010 Apr 1;6(4):e1000848. doi: 10.1371/journal.ppat.1000848.

4.

Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner.

Semighini CP, Averette AF, Perfect JR, Heitman J.

PLoS Pathog. 2011 Nov;7(11):e1002364. doi: 10.1371/journal.ppat.1002364. Epub 2011 Nov 17.

5.

Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment.

Sionov E, Chang YC, Kwon-Chung KJ.

Antimicrob Agents Chemother. 2013 Oct;57(10):5127-30. doi: 10.1128/AAC.00694-13. Epub 2013 Jul 8.

6.

Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.

Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ.

Antimicrob Agents Chemother. 2009 Jul;53(7):2804-15. doi: 10.1128/AAC.00295-09. Epub 2009 May 4.

7.

Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole.

Sionov E, Chang YC, Garraffo HM, Dolan MA, Ghannoum MA, Kwon-Chung KJ.

Antimicrob Agents Chemother. 2012 Mar;56(3):1162-9. doi: 10.1128/AAC.05502-11. Epub 2011 Dec 12.

8.

Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole.

Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L, Morace G, Fadda G.

Mol Microbiol. 2003 Jan;47(2):357-71.

PMID:
12519188
9.

Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans.

Yamazumi T, Pfaller MA, Messer SA, Houston AK, Boyken L, Hollis RJ, Furuta I, Jones RN.

J Clin Microbiol. 2003 Jan;41(1):267-72.

10.

Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A.

Florio AR, Ferrari S, De Carolis E, Torelli R, Fadda G, Sanguinetti M, Sanglard D, Posteraro B.

BMC Microbiol. 2011 May 11;11:97. doi: 10.1186/1471-2180-11-97.

11.

Heteroresistance of Cryptococcus gattii to fluconazole.

Varma A, Kwon-Chung KJ.

Antimicrob Agents Chemother. 2010 Jun;54(6):2303-11. doi: 10.1128/AAC.00153-10. Epub 2010 Apr 12.

12.

A defect in iron uptake enhances the susceptibility of Cryptococcus neoformans to azole antifungal drugs.

Kim J, Cho YJ, Do E, Choi J, Hu G, Cadieux B, Chun J, Lee Y, Kronstad JW, Jung WH.

Fungal Genet Biol. 2012 Nov;49(11):955-66. doi: 10.1016/j.fgb.2012.08.006. Epub 2012 Sep 4.

13.

Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.

Paul S, Doering TL, Moye-Rowley WS.

Fungal Genet Biol. 2015 Jan;74:1-9. doi: 10.1016/j.fgb.2014.10.015. Epub 2014 Nov 1.

14.

Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method.

Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN.

Diagn Microbiol Infect Dis. 2011 Nov;71(3):252-9. doi: 10.1016/j.diagmicrobio.2011.07.007. Epub 2011 Sep 13.

PMID:
21917395
15.

Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans.

Lee H, Khanal Lamichhane A, Garraffo HM, Kwon-Chung KJ, Chang YC.

Mol Microbiol. 2012 Apr;84(1):130-46. doi: 10.1111/j.1365-2958.2012.08016.x. Epub 2012 Mar 15.

16.

Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.

Khyriem AB, Sujatha S, Parija SC.

Indian J Pathol Microbiol. 2006 Apr;49(2):307-8.

PMID:
16933750
17.

Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans.

Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-Chung KJ.

Antimicrob Agents Chemother. 1999 Aug;43(8):1856-61.

18.

Overexpression of TUF1 restores respiratory growth and fluconazole sensitivity to a Cryptococcus neoformans vad1Delta mutant.

Panepinto JC, Misener AL, Oliver BG, Hu G, Park YD, Shin S, White TC, Williamson PR.

Microbiology. 2010 Aug;156(Pt 8):2558-65. doi: 10.1099/mic.0.035923-0. Epub 2010 Apr 29.

19.

Azole resistance in Cryptococcus gattii from the Pacific Northwest: Investigation of the role of ERG11.

Gast CE, Basso LR Jr, Bruzual I, Wong B.

Antimicrob Agents Chemother. 2013 Nov;57(11):5478-85. doi: 10.1128/AAC.02287-12. Epub 2013 Aug 26.

20.

Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi.

Mansfield BE, Oltean HN, Oliver BG, Hoot SJ, Leyde SE, Hedstrom L, White TC.

PLoS Pathog. 2010 Sep 30;6(9):e1001126. doi: 10.1371/journal.ppat.1001126.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk